Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
AMD shares rise ahead of strong earnings forecast, outpacing sector and S&P 500
Meta shares fall after tax charge and capex hike, raising concerns about timeline and scale of AI returns beyond ads.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
AMD shares rise ahead of strong earnings forecast, outpacing sector and S&P 500
Meta shares fall after tax charge and capex hike, raising concerns about timeline and scale of AI returns beyond ads.